Psoriasis (PsO)
Conditions
Brief summary
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Detailed description
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Interventions
None listed
Sponsors
Julia Tatjana Maul
University of Zurich
University Hospital, Zürich
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed General Consent Form, or equivalent document * Confirmed diagnosis of Psoriasis
Exclusion criteria
* Inability to provide informed consent. * Datasets with ambiguous or unclear diagnosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Psoriasis Area Severity Index (PASI) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Composite clinician-assessed measure of psoriasis severity based on erythema, scaling, thickness, and affected body surface area; total score ranges from 0 to 72, with higher scores indicating more severe disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dermatology Life Quality Index (DLQI) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment. |
| Nail Psoriasis Severity Index (NAPSI) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Clinician-assessed measure of nail psoriasis severity based on nail matrix and nail bed involvement; scores range from 0-80 for fingernails and 0-80 for toenails; total score ranges from 0-160, with higher scores indicating more severe nail disease. |
| Numerical Rating Scale (NRS) for disease severity | Baseline and follow-up visits every 6-12 months for up to 5 years. | Patient-reported assessment of psoriasis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable). |
| Physician Global Assessment (PGA) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Clinician-assessed global measure of psoriasis severity on a scale from 0 (clear) to 4 (severe). |
| Body Surface Area (BSA) | Baseline and follow-up visits every 6-12 months for up to 5 years. | Percentage of total body surface area affected by psoriasis, ranging from 0% to 100%. |
Countries
Switzerland
Contacts
CONTACTJulia-Tatjana Maul
CONTACTJohannes A Didaskalu, Prof. Dr. med.
PRINCIPAL_INVESTIGATORJulia-Tatjana Maul, Prof. Dr. med.
University of Zurich
Outcome results
None listed